BridgeBio Pharma, Inc. Payments to Acquire Debt Securities, Available-for-sale
BridgeBio Pharma, Inc. (BBIO) reported Payments to Acquire Debt Securities, Available-for-sale of $63.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-10
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $11.27M, a 42.53% increase year-over-year.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $52.67M.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $17.32M.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $2.97M.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $28.20M, a 69.94% decline from fiscal 2024.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $93.81M, a 215.59% increase from fiscal 2023.
- BridgeBio Pharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $29.73M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $63.94M 10-Q · filed 2026-08-10 | $81.26M derived: sum of 3 quarters · filed 2026-08-10 | $84.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $52.67M 10-Q · filed 2026-05-07 | $69.99M derived: sum of 2 quarters · filed 2026-05-07 | $72.95M derived: sum of 3 quarters · filed 2026-05-07 | $80.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $17.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $20.29M derived: sum of 2 quarters · filed 2026-02-24 | $28.20M derived: sum of 3 quarters · filed 2026-08-10 | $28.20M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $10.88M derived: sum of 2 quarters · filed 2026-08-10 | $10.88M 10-Q · filed 2025-10-29 | $10.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $7.91M 10-Q · filed 2026-08-10 | $7.91M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $93.81M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $93.81M 10-Q · filed 2025-10-29 | |||
| 2023-12-31 | $29.73M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |